TrialArthritis research & therapy2022

Efficacy and safety of the biosimilar denosumab candidate (Arylia) compared to the reference product (Prolia®) in postmenopausal osteoporosis: a phase III, randomized, two-armed, double-blind, parallel, active-controlled, and noninferiority clinical trial.

Ahmadreza Jamshidi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.